



Radius Health, Inc.
Investor Relations Department
950 Winter St, North Building 1st Floor
North Building 1st Floor
Waltham, MA 02451
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: RDUS

Last Trade:	42.34
Trade Time:	4:00 PM ET Jul 20, 2017
Change:	-0.12 (-0.283%)
Day Range	41.35 - 42.89
52-Week Range	31.58 - 59.88
Volume	812,248

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product, TYMLOS (abaloparatide) Injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius clinical ... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Jul 18, 2017
[Radius Health Announces New Employment Inducement Grant](#)

Jul 17, 2017
[Radius Health Appoints Jesper Høiland as President and Chief Executive Officer To Lead The Next Stage Of Growth and Value Creation As A Fully Integrated Commercial Biotech Company](#)

Jul 13, 2017
[Radius Health Announces License and Development Agreement for Abaloparatide-SC with Teijin Limited in Japan](#)

Jul 7, 2017
[Radius Health to Announce Second Quarter 2017 Financial Results, Host Conference Call and Live Webcast on August 3, 2017](#)

Jun 4, 2017
[Radius Presents Positive Data From A Fully Enrolled Ongoing Phase I Study for Investigational Drug Elacestrant \(RAD1901\) at the 2017 American Society of Clinical Oncology Annual Meeting \(ASCO\)](#)

Upcoming Events [\[View all \]](#)

Aug 3, 2017 4:30 PM ET
[Radius Health Second Quarter 2017 Financial Results](#)

Financials [\[View all \]](#)

Feb 24, 2017
[Annual Report \(10-K\)](#)

Apr 21, 2017
[Proxy Statement \(DEF 14A\)](#)

May 2, 2017
[Quarterly Report \(10-Q\)](#)

Nov 3, 2016
[Quarterly Report \(10-Q\)](#)

Aug 4, 2016
[Quarterly Report \(10-Q\)](#)